Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients With Combined Pulmonary Fibrosis and Emphysema: Data From the INBUILD Trial

被引：0
|
作者：
Cottin, V. [1 ]
Flaherty, K. R. [2 ]
Inoue, Y. [3 ]
Valenzuela, C. [4 ]
Mueller, H. [5 ]
Rohr, K. B. [6 ]
Wells, A. U. [7 ,8 ]
机构：
[1] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis,UMR 754, Lyon, France
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Natl Hosp Org, Clin Res Ctr, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[4] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Imperial Coll, Natl Inst Hlth Res, Resp Biomed Res Unit, Royal Brompton & Harefield NHS Fdn Trust, London, England
[8] Imperial Coll, Natl Heart & Lung Inst, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2578
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effects of Nintedanib on Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Subgroup Analyses of the INBUILD Trial
    Maher, T. M.
    Jenkins, R. G.
    Bonella, F.
    Assassi, S.
    Noth, I.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K. B.
    Kolb, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [32] Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Data From the INBUILD Trial
    Noth, I.
    Maher, T. M.
    Bonella, F.
    Assassi, S.
    Jenkins, R. G.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K. B.
    Kolb, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [33] The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis
    Assayag, Deborah
    Vittinghoff, Eric
    Ryerson, Christopher J.
    Cocconcelli, Elisabetta
    Tonelli, Roberto
    Hu, Xiaowen
    Elicker, Brett M.
    Golden, Jeffrey A.
    Jones, Kirk D.
    King, Talmadge E., Jr.
    Koth, Laura L.
    Lee, Joyce S.
    Ley, Brett
    Shum, Anthony K.
    Wolters, Paul J.
    Ryu, Jay H.
    Collard, Harold R.
    RESPIRATORY MEDICINE, 2015, 109 (08) : 1058 - 1062
  • [34] Relative Versus Absolute Decline in Forced Vital Capacity in Progressive Pulmonary Fibrosis
    Castro, Horacio Matias
    Furcada, Joaquin Maritano
    Enghelmayer, Juan Ignacio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (12): : 843 - 844
  • [35] Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD- ON
    Matteson, Eric
    Antin-Ozerkis, Danielle
    Bonella, Francesco
    Chaudhuri, Nazia
    Cottin, Vincent
    Mueller, Heiko
    Sambevski, Steven
    Wuyts, Wim A.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4260 - 4262
  • [36] No Effect of Dose Adjustments on Long-Term Reduction in FVC Decline With Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Huggins, John
    Meyer, Keith
    Stansen, Wibke
    Quaresma, Manuel
    Kreuter, Michael
    CHEST, 2017, 152 (04) : 452A - 452A
  • [37] NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSCIS TRIAL
    Distler, Oliver
    Highland, Kristin
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Kuwana, Masataka
    Maher, Toby M.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 75 - 75
  • [38] Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS® trial
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Fischer, A.
    Mayes, M. D.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Stowasser, S.
    Kuwana, M.
    Maher, T. M.
    SWISS MEDICAL WEEKLY, 2019, : 12S - 12S
  • [39] Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib
    Mondoni, Michele
    Varone, Francesco
    Alfano, Fausta
    Muscato, Giuseppe
    Conti, Caterina
    Saderi, Laura
    Iovene, Bruno
    Di Marco, Fabiano
    Vancheri, Carlo
    Richeldi, Luca
    Centanni, Stefano
    Sotgiu, Giovanni
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (07): : 464 - 466
  • [40] First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of aecurrency sign50 % of Predicted Value
    Wuyts, Wim A.
    Kolb, Martin
    Stowasser, Susanne
    Stansen, Wibke
    Huggins, John T.
    Raghu, Ganesh
    LUNG, 2016, 194 (05) : 739 - 743
12345